{
    "clinical_study": {
        "@rank": "158332", 
        "arm_group": {
            "arm_group_label": "Arm 1", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The treatment of cerebrotendinous xanthomatosis an in born error of bile acid synthesis with\n      chenodeoxycholic acid.  Patients with this disease over produce cholestanol and bile acid\n      precursors because of the block in synthesis. Replacement with chenodeoxycholic acid shut\n      down abnormal pathway and reduces elevated level of cholestanol  and improves the clinical\n      syndrome."
        }, 
        "brief_title": "Cholestanol in Humans", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": "Cerebrotendinous Xanthomatosis", 
        "condition_browse": {
            "mesh_term": [
                "Xanthomatosis", 
                "Xanthomatosis, Cerebrotendinous"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cerebrotendinous xanthomatosis is a recessively inherited in born of bile acid synthesis due\n      to a mutation  in sterol 27-hydroxylase (CYP27A1).  Patients with this disease suffer from\n      xanthomas located in the brain and tendon, accelerated atherosclerosis progression\n      neurologic disease and cataracts.  Plasma cholesterol levels are normal but cholestanol and\n      C-27 bile alcohol that precursor of bile acid synthesis accumulate and are believe are\n      responsible for the atherosclerosis, xanthomas and neurologic disease. Analysis of the bile\n      reveal a severe sufficiency of the primary bile acid chenodeoxycholic acid that can not be\n      produce because of the inherited defect. However, replacement of chenodeoxycholic acid in\n      the enterohepatic  pool inhibit abnormal bile acid synthesis and reduces the elevated level\n      of cholestanol and C-27 bile alcohol this therapy halt the neurologic disease and prevents\n      symptomatic atherosclerosis developing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with clinical and biochemical findings of cerebrotendinous xanthomatosis.\n        Elevated levels of  serum cholestanol and bile acid precursors.\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 3, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00018694", 
            "org_study_id": "GAST-007-99S"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1", 
            "intervention_name": "Chenodeoxycholic Acid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Chenodeoxycholic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bile acid synthesis", 
            "chenodeoxycholic acid", 
            "sterol 27-hydroxylase"
        ], 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "East Orange", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07018"
                }, 
                "name": "VA New Jersey Health Care System, East Orange"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Biologic Significance of Cholestanol in Man", 
        "overall_official": {
            "affiliation": "VA New Jersey Health Care System, East Orange", 
            "last_name": "Gerald Salen", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00018694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Department of Veterans Affairs", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 1999", 
        "study_design": "Allocation: Non-Randomized, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }, 
    "geocoordinates": {
        "VA New Jersey Health Care System, East Orange": "40.767 -74.205"
    }
}